Skip to main content

Table 1 Composite overall response in laBCC determined by ERIVANCE-like vs mRECIST criteria

From: Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis

MRIa

Photographb

Histologyc

Composite overall response

mRECISTd,e

ERIVANCE-like criteria

CR

CR

Negative

CRc

CR

PR (scar/fibrosis only) or SD (scar/fibrosis only)

Negative

NA

Negative

NA

CR

Negative

CRc

CR

PR (scar/fibrosis only) or SD (scar/fibrosis only)

Negative

PR

CR

Negative

PR

CR

PR (scar/fibrosis only) or SD (scar/fibrosis only)

Negative

SD

CR

Negative

PR

CR

PR (scar/fibrosis only) or SD (scar/fibrosis only)

Negative

CR

PR

Negative

PR

CR

PR

SD

NA

CR

SD

Negative

SD

CR

PR

PR

NA

Negative

PR

CR

CR

SD

Positive or unknown

SD

PR

SD (scarring/fibrosis only)

PR

SD

Positive or unknown

SD

PR

SD (scarring/fibrosis only)

  1. aMeasurability per central review per RECIST v1.1 [23]
  2. bPR ≥50% reduction in the sum of perpendicular products; PD ≥25% increase in the sum of products per WHO criteria [25]
  3. cConfirmed CRs required multiple punch biopsy samples per lesion
  4. dAn independent review committee reevaluated all assessments for the laBCC cohort to determine a composite response
  5. eSince posttreatment ulceration, cyst formation, and scarring/fibrosis may be considered treatment effects and are not necessarily indicative of disease progression in laBCC, “scarring/fibrosis only” was allowed per mRECIST criteria, given that the other measures such as histology and MRI also showed no signs of disease progression
  6. CR complete response, laBCC locally advanced basal cell carcinoma, mRECIST modified RECIST, MRI magnetic resonance imaging, NA not available, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease, WHO World Health Organization